{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:49:56Z","timestamp":1774684196937,"version":"3.50.1"},"reference-count":7,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ygyno.2021.02.014","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T14:09:30Z","timestamp":1614089370000},"page":"496-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Utilizing an interim futility analysis of the OVAL study (VB-111-701\/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer"],"prefix":"10.1016","volume":"161","author":[{"given":"Rebecca C.","family":"Arend","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronnie","family":"Shapira-Frommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishnansu S.","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Rachmilewitz Minei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shifra Fain","family":"Shmueli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Lavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ygyno.2021.02.014_bb0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.ygyno.2021.02.014_bb0010","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1172\/JCI200420007","article-title":"Transcription-controlled gene therapy against tumor angiogenesis","volume":"113","author":"Greenberger","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.014_bb0015","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1172\/JCI117784","article-title":"Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter","volume":"95","author":"Harats","year":"1995","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.ygyno.2021.02.014_bb0020","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/sj.gt.3301472","article-title":"Tissue-specific gene therapy directed to tumor angiogenesis","volume":"8","author":"Varda-Bloom","year":"2001","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.014_bb0025","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ygyno.2020.02.034","article-title":"Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I\/II study are associated with an immunotherapeutic effect","volume":"157","author":"Arend","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.02.014_bb0030","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/sim.7157","article-title":"Designing therapeutic cancer vaccine trials with delayed treatment effect","volume":"36","author":"Xu","year":"2017","journal-title":"Stat. Med."},{"issue":"13","key":"10.1016\/j.ygyno.2021.02.014_bb0035","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821001517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821001517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:28:33Z","timestamp":1715819313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821001517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0090825821001517"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.02.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilizing an interim futility analysis of the OVAL study (VB-111-701\/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}